Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official
August 23, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
- Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
- MHLW Advisory Panel to Review Budesonide Rectal Foam on Sept. 1
August 21, 2017
- 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
- NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
- “Pediatric Treatment” Excluded from Appraisal Adjustment Factors in Pilot Program: Chuikyo
August 10, 2017
- MHLW Wants to Use Past Surveys, Overseas Examples for ICER Yardstick in CEA Pilot Program, Plan Draws Fire from Payers Reps: Chuikyo
August 10, 2017
- Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
- New Measures Needed to Ramp Up Generic Use: Chuikyo
August 10, 2017
- MHLW Orders Label Revisions for Warfarin, 3 Other APIs
August 7, 2017
- (Update) Katsunobu Kato Tapped as New Health Minister
August 4, 2017
- Clinical Research Law to Apply to “Nearly All Drug-Related Clinical Research” Funded by Drug Makers: MHLW
August 4, 2017
- Katsunobu Kato Tapped as New Health Minister
August 3, 2017
- “We Should Increase Our Efforts” to Promote Pharmaceutical Industry: New Health Policy Bureau Chief Takeda
August 3, 2017
- MHLW Advisory Panel Recommends Approval for Zetia/Lipitor Combo
August 3, 2017
- Bayer’s ADR Reporting Delay “Very Regrettable”: Shiozaki
August 2, 2017
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…